U.S. Stock News

NYSE:PSTG
NYSE:PSTGTech

How Everpure’s Strong Q4, Buybacks and AI Deal Will Impact Everpure (PSTG) Investors

Everpure Inc., formerly Pure Storage, has reported fourth-quarter revenue of US$1,058.9 million and net income of US$100.25 million, outlined full-year results, issued revenue guidance for fiscal 2027, completed a US$570.8 million share repurchase program, and confirmed a pending acquisition of data intelligence firm 1touch. Together with its rebrand and AI-focused 1touch acquisition, Everpure is signaling a shift from pure storage hardware toward a broader, software-rich data management and...
NYSE:AMRC
NYSE:AMRCConstruction

Does Ameresco’s (AMRC) Landfill Solar Push Reveal a Durable Edge in Community-Scale Clean Energy?

In February 2026, Ameresco and Luminace reported the completion of the 5.740 MW Coventry Landfill Solar project in Rhode Island, while Ameresco also partnered with Bradford Exempted Village School District in Ohio on a 304 kW rooftop solar system backed by state grant funding. These projects highlight Ameresco’s ability to turn constrained landfill sites and public school rooftops into income-generating clean energy assets for local communities. Next, we’ll examine how Ameresco’s work...
NasdaqGS:SATS
NasdaqGS:SATSMedia

EchoStar Leans On Boost Mobile Galaxy S26 Push To Drive Growth

EchoStar’s Boost Mobile has opened preorders for Samsung’s Galaxy S26 lineup with savings of up to $1,000 without requiring a device trade in. The offers follow Boost Mobile’s recent rollout of the moto g 2026 series, extending a rapid push of new devices and promotions. The campaign aims to draw new wireless customers and retain existing ones through aggressive handset pricing and differentiated plan options. EchoStar, listed as NasdaqGS:SATS, is leaning heavily on Boost Mobile’s device...
NYSE:RNG
NYSE:RNGSoftware

Why RingCentral (RNG) Is Up 16.6% After Launching Dividend, Bigger Buyback and New AI Push

Earlier in February 2026, RingCentral reported fourth-quarter 2025 results showing revenue rising to US$644.03 million and a shift from a net loss to US$22.97 million in net income, issued 2026 guidance calling for US$640–US$645 million in first-quarter revenue and 4%–5% full-year revenue growth, initiated a quarterly US$0.075 dividend, expanded its buyback authorization to US$500 million after repurchasing 31.61 million shares for US$967.01 million, and announced a broad integration of...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Assessing Zebra Technologies (ZBRA) Valuation After New AI Powered Machine Vision Deployment

Zebra Technologies (ZBRA) is back in focus after EBI Electric adopted its AltiZ 3D sensors for the new Inspector T lumber scanning system, pairing AI models with machine vision to sharpen yield and cost control. See our latest analysis for Zebra Technologies. Those product wins and the recent buyback and guidance update come against a mixed price backdrop, with the latest share price at $239.01, a 1 day share price return of 1.35% but a 1 year total shareholder return decline of 25.19%,...
NYSE:NRG
NYSE:NRGElectric Utilities

NRG Energy (NRG) Margin Compression Tests Bullish Profitability Narratives After FY 2025 Results

NRG Energy (NRG) closed out FY 2025 with fourth quarter revenue of US$7.8b and basic EPS of US$0.26, alongside net income of US$50m. Trailing twelve month figures show revenue of US$30.7b, EPS of US$4.09 and net income of US$797m. The company has seen revenue move from US$28.1b to US$30.7b on a trailing basis across the periods provided, with trailing EPS shifting from US$5.14 to US$4.09 over the same window. This sets up a picture where modest top line progress sits against tighter...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is It Time To Reconsider BeOne Medicines (ONC) After Mixed Recent Share Returns?

If you are trying to figure out whether BeOne Medicines is attractively priced or already reflects its potential, you are in the right place. The stock closed at US$352.23, with a 7 day return of a 0.6% decline, a 30 day return of 4.8%, and longer term returns of 13.2% year to date, 26.5% over 1 year, 46.6% over 3 years and 21.8% over 5 years. These mixed short term and longer term returns often prompt investors to look more closely at what might be driving sentiment and expectations. In...
NYSE:RCUS
NYSE:RCUSBiotechs

Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals

If you are wondering whether Arcus Biosciences is attractively priced today, this article walks through what the current share price could imply about the company’s underlying value. The stock last closed at US$20.27, with returns of 4.3% over 7 days, a 9.8% decline over 30 days, a 13.0% decline year to date, a 99.9% gain over 1 year, a 16.4% return over 3 years and a 41.3% decline over 5 years. Recent attention around Arcus Biosciences has largely focused on its pipeline and partnerships in...
NasdaqGS:TXRH
NasdaqGS:TXRHHospitality

Is It Too Late To Consider Texas Roadhouse (TXRH) After Recent Share Price Softness

Wondering if Texas Roadhouse at about US$181.78 a share still offers value, or if most of the opportunity is already priced in? This article walks through what the numbers are actually saying about the stock. The share price has eased with an estimated 2.7% decline over the last 7 days and a 2.3% decline over the last 30 days, while longer term returns sit at 6.1% year to date and 5.1% over 1 year, with very large gains of 87.6% over 3 years and 111.3% over 5 years. Recent coverage around...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

Did Booking’s Cost‑Saving Drive, Stock Split and New Dividend Just Shift Booking Holdings' (BKNG) Investment Narrative?

Earlier in February, Booking Holdings reported fourth‑quarter 2025 results showing revenue rising to US$6,349 million and net income to US$1,428 million, alongside announcing a 25‑for‑1 stock split and a new quarterly dividend of US$10.50 per share. The earnings release also highlighted the Transformation Program’s US$550 million in annual cost savings and stronger margins, underlining how cost discipline is reshaping Booking’s profitability profile. With the Transformation Program’s cost...
NYSE:NOMD
NYSE:NOMDFood

Nomad Foods Boosts 2025 Cash Returns As 2026 Reset Targets Value Creation

Nomad Foods (NYSE:NOMD) has set a shareholder capital return plan for 2025 that lifts dividends and share repurchases by 38% year on year. The company is also preparing broad organizational and planning changes for 2026 aimed at performance and value creation. This combination of higher cash returns and a reset year ahead marks a clear shift in how Nomad Foods is approaching capital allocation and its business setup. For investors looking at the frozen foods group today, Nomad Foods trades...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

Is It Time To Reassess Flex (FLEX) After Its Strong 1 Year Share Price Run?

If you are wondering whether Flex shares still offer value after a strong run, this article walks through what the current price might be implying about the company. Flex recently closed at US$65.67, with a 7 day return of a 0.2% decline, a 30 day return of 3.0%, a year to date return of 3.1% and a 1 year return of 65.2%, while the 3 year return is very large and the 5 year return is also very large. Recent news coverage has tended to focus on Flex as an established player in electronics...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

Innoviva’s NUZOLVENCE Approval And Buyback Reframe Growth And Valuation Story

Innoviva (NasdaqGS:INVA) received FDA approval for NUZOLVENCE, a first in class treatment for uncomplicated urogenital gonorrhea. The company announced a US$125 million share repurchase program alongside the approval. These updates point to meaningful shifts in Innoviva's specialty therapeutics focus and capital allocation approach. For you as an investor, NUZOLVENCE adds a new approved therapy to Innoviva's portfolio, aligning with its push in specialty therapeutics. Gonorrhea treatment is...
NYSE:GAM
NYSE:GAMCapital Markets

How General American Investors’ 2025 Earnings Gap Between Revenue and Profit Could Reshape GAM’s Narrative

General American Investors Company, Inc. has reported its full-year 2025 results, posting revenue of US$24.31 million and net income of US$339.84 million for the year ended December 31, 2025. The contrast between relatively modest revenue and very large net income highlights how investment gains can significantly shape this closed-end fund’s financial profile. With this unusually wide gap between revenue and net income, we’ll explore what the latest earnings mean for General American...
NYSE:PFS
NYSE:PFSBanks

A Look At Provident Financial Services (PFS) Valuation After Recent Share Price Gains

Context for Provident Financial Services (PFS) Provident Financial Services (PFS) has attracted fresh attention after recent share price moves, with the stock roughly flat over the past day but showing mixed returns over the past week, month and past 3 months. See our latest analysis for Provident Financial Services. At a share price of US$21.91, Provident Financial Services has paired a softer 7 day share price return of 4.61% with a stronger 30 day gain of 6.41%. Its 1 year total...
NasdaqGS:WYNN
NasdaqGS:WYNNHospitality

Why Wynn Resorts (WYNN) Is Down 7.6% After Cyberattack Fallout And Profitability Pressures - And What's Next

In the fourth quarter of 2025, Wynn Resorts reported revenue of US$1,865.98 million and net income of US$100.03 million, while also declaring a US$0.25 per-share dividend and later confirming a cyberattack that exposed hundreds of thousands of employee records. The combination of weaker quarterly profitability, an ongoing data breach investigation, and a class-action lawsuit over alleged cybersecurity failures raises fresh questions about Wynn’s risk profile and operational resilience...
NYSE:EME
NYSE:EMEConstruction

A Look At EMCOR Group (EME) Valuation After Strong Multi Year Shareholder Returns

Why EMCOR Group (EME) Is On Investors’ Radar Today EMCOR Group (EME) has attracted fresh attention after recent trading left the shares around $801.80, prompting investors to reassess the company’s fundamentals, recent returns, and valuation signals. See our latest analysis for EMCOR Group. While EMCOR Group’s share price eased slightly in the latest session, its 30-day share price return of 11.94% and year-to-date gain of 25.55% sit alongside a very large 5-year total shareholder return of...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

A Look At Intellia Therapeutics (NTLA) Valuation After Earnings Beat Trial Progress And FDA Hold Lift

Intellia Therapeutics (NTLA) is in focus after a busy stretch, with Q4 2025 results exceeding earnings and revenue expectations, encouraging hereditary angioedema trial data, and an FDA clinical hold lifted on its partnered gene editing drug. See our latest analysis for Intellia Therapeutics. At a share price of $13.42, Intellia has seen a 49.28% 90 day share price return and a 45.71% year to date share price return. However, the 3 year total shareholder return of a 69.49% decline shows that...
NasdaqGS:ADEA
NasdaqGS:ADEASoftware

Why Adeia (ADEA) Is Up 11.5% After Record 2025 Results And Microsoft Licensing Deal – And What's Next

Adeia Inc. recently reported fourth-quarter 2025 revenue of US$182.64 million and net income of US$73.71 million, delivering record full-year results and issuing 2026 GAAP revenue guidance of US$395.0 million to US$435.0 million alongside a quarterly dividend of US$0.05 per share. These results were supported by 26 new license agreements, including multi-year deals with companies such as Microsoft and Disney, as Adeia continues shifting its revenue mix toward OTT and semiconductor markets...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

Does Post‑Earnings Analyst Optimism Around clonoSEQ Adoption Change The Bull Case For Adaptive (ADPT)?

In recent days, Adaptive Biotechnologies received supportive research updates from TD Cowen, BTIG, and JPMorgan following the company’s strong Q4 results and improved outlook. Analysts emphasized growing community adoption of its clonoSEQ minimal residual disease testing and progress on new indications, underscoring Adaptive’s position within specialty laboratory diagnostics. Next, we’ll examine how this post‑earnings analyst optimism, particularly around clonoSEQ’s community adoption, may...
NYSE:TDY
NYSE:TDYElectronic

What Teledyne Technologies (TDY)'s Lepton XDS Dual-Spectrum Camera Launch Means For Shareholders

In February 2026, Teledyne FLIR OEM launched the Lepton XDS, an ITAR-free, dual-thermal-and-visible camera module that embeds its MSX edge-enhancement technology and Prism ISP software into a compact, low-power package for embedded, mobile, and industrial OEM applications. By combining radiometric thermal sensing, real-time thermal-visible fusion, and an industry-first RJPEG output in a SWaP-optimized module, Teledyne is pushing advanced imaging intelligence into space- and power-constrained...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

Polestar (PSNY) Is Up 20.4% After Unveiling Four-Model Expansion And Major Retail Buildout Plans

Earlier this month, Polestar announced its largest model expansion to date, planning four new vehicles by 2028, while targeting low double-digit volume growth in 2026 and a 30% expansion of its retail network. The company also highlighted meaningful progress on sustainability and technology, including emissions cuts per vehicle and the climate-focused Polestar 0 program, supported by a recent US$700,000,000 funding raise. We’ll now examine how this expanded four-model rollout and retail...
NYSE:PNC
NYSE:PNCBanks

Does PNC’s FirstBank Deal and Data‑Driven Expansion Strategy Reshape The Bull Case For PNC (PNC)?

Recently, PNC Financial Services Group announced the retirement of long-time executive Richard Bynum and promoted Stacy Juchno to chief corporate responsibility officer while elevating Mike Abriatis to general auditor and executive committee member, alongside unveiling new data products, community investments, lending deals and acquisition plans including an agreement to acquire FirstBank in Colorado and Arizona. Together with its new PNC Monthly Consumer Health Check and expanded affordable...
NYSE:PRU
NYSE:PRUInsurance

Is Prudential Financial (PRU) Pricing Look Attractive After Recent Share Price Weakness

If you are wondering whether Prudential Financial at around US$100.86 is offering fair value or a potential bargain, you are in the right place. The share price has seen a 3.3% decline over the last 7 days and a 7.5% decline over the last 30 days. The 3 year and 5 year returns of 17.3% and 43.5% give longer term holders a different picture compared with the 11.4% year to date and 5.1% 1 year declines. Recent coverage of Prudential Financial has focused on how investors interpret these mixed...